MX2021004191A - Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. - Google Patents
Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.Info
- Publication number
- MX2021004191A MX2021004191A MX2021004191A MX2021004191A MX2021004191A MX 2021004191 A MX2021004191 A MX 2021004191A MX 2021004191 A MX2021004191 A MX 2021004191A MX 2021004191 A MX2021004191 A MX 2021004191A MX 2021004191 A MX2021004191 A MX 2021004191A
- Authority
- MX
- Mexico
- Prior art keywords
- bifunctional compounds
- proteosome pathway
- ubiquitin proteosome
- degrading
- via ubiquitin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000044159 Ubiquitin Human genes 0.000 title abstract 2
- 108090000848 Ubiquitin Proteins 0.000 title abstract 2
- 230000000593 degrading effect Effects 0.000 title abstract 2
- 230000037361 pathway Effects 0.000 title abstract 2
- 230000001588 bifunctional effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Abstract
La presente invención se refiere a compuestos útiles para degradar a BTK mediante una trayectoria proteolítica de ubiquitina. La invención también proporciona composiciones farmacéuticamente aceptables que comprenden tales compuestos y métodos para usar las composiciones en el tratamiento de varias enfermedades, condiciones, o trastornos.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862745786P | 2018-10-15 | 2018-10-15 | |
US201862767819P | 2018-11-15 | 2018-11-15 | |
US201962836398P | 2019-04-19 | 2019-04-19 | |
US201962887812P | 2019-08-16 | 2019-08-16 | |
US201962901984P | 2019-09-18 | 2019-09-18 | |
PCT/US2019/056112 WO2020081450A1 (en) | 2018-10-15 | 2019-10-14 | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004191A true MX2021004191A (es) | 2021-05-27 |
Family
ID=68425337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004191A MX2021004191A (es) | 2018-10-15 | 2019-10-14 | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
Country Status (11)
Country | Link |
---|---|
US (3) | US11479556B1 (es) |
EP (1) | EP3867242A1 (es) |
JP (1) | JP2022508705A (es) |
KR (1) | KR20210077719A (es) |
CN (1) | CN113412259A (es) |
AU (2) | AU2019360928B2 (es) |
BR (2) | BR112021007115A2 (es) |
CA (1) | CA3115526A1 (es) |
IL (1) | IL281904A (es) |
MX (1) | MX2021004191A (es) |
WO (1) | WO2020081450A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
AU2018388404B2 (en) | 2017-12-22 | 2023-11-02 | HiberCell Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
US11479556B1 (en) | 2018-10-15 | 2022-10-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
KR20210149757A (ko) | 2019-04-09 | 2021-12-09 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
CN114206855A (zh) | 2019-05-17 | 2022-03-18 | 紐力克斯治疗公司 | 用于Cbl-b抑制的氰基环丁基类化合物及其用途 |
CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
TW202108571A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
AU2020303696A1 (en) | 2019-06-26 | 2022-01-06 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof |
WO2021113557A1 (en) * | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
JP2023524999A (ja) * | 2020-05-06 | 2023-06-14 | ニューリックス セラピューティクス,インコーポレイテッド | 造血前駆体キナーゼの二官能性分解物質およびその治療的使用 |
EP4146639A1 (en) | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
AU2021376415A1 (en) | 2020-11-06 | 2023-06-22 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
WO2022120355A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
WO2022270994A1 (ko) | 2021-06-25 | 2022-12-29 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
KR102637915B1 (ko) * | 2021-06-25 | 2024-02-19 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
KR20240029070A (ko) * | 2021-07-01 | 2024-03-05 | 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 | 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용 |
IL309666A (en) | 2021-07-09 | 2024-02-01 | Plexium Inc | Aryl compounds and pharmaceutical preparations that modulate IKZF2 |
AU2022310182A1 (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with diminished imid activity |
AU2022313210A1 (en) | 2021-07-23 | 2024-02-08 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
WO2023009709A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Pyrazolo piperazines as jak2 inhibitors |
WO2023059582A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
WO2023076303A1 (en) * | 2021-10-26 | 2023-05-04 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
TW202325300A (zh) * | 2021-11-18 | 2023-07-01 | 大陸商正大天晴藥業集團股份有限公司 | 稠合醯亞胺類衍生物及其應用 |
WO2023088477A1 (zh) * | 2021-11-22 | 2023-05-25 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
CN115894450B (zh) * | 2021-11-30 | 2023-09-12 | 山东如至生物医药科技有限公司 | 一种新型多环类化合物及其组合物和用途 |
WO2023143249A1 (zh) * | 2022-01-28 | 2023-08-03 | 上海齐鲁制药研究中心有限公司 | 靶向malt1的蛋白降解化合物 |
WO2023227080A1 (zh) * | 2022-05-25 | 2023-11-30 | 百极弘烨(南通)医药科技有限公司 | 一种protac化合物、含其的药物组合物及其制备方法和应用 |
WO2024043334A1 (ja) * | 2022-08-26 | 2024-02-29 | 富士フイルム株式会社 | 新規なピペラジン誘導体又はその塩及び医薬組成物 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070054355A1 (en) | 2003-03-05 | 2007-03-08 | Yuval Reiss | Cbl-b polypeptides, complexes and related methods |
EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
ES2566502T3 (es) | 2006-09-13 | 2016-04-13 | The Trustees Of Columbia University In The City Of New York | Agentes y métodos para provocar una respuesta inmune antitumoral |
AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
NZ586916A (en) | 2008-02-05 | 2012-06-29 | Hoffmann La Roche | Novel pyridinones and pyridazinones |
JP2012529535A (ja) * | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
CN110818724B (zh) | 2010-05-07 | 2020-11-13 | 吉利德康涅狄格有限公司 | 吡啶酮和氮杂吡啶酮化合物及使用方法 |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
US20130110678A1 (en) | 2011-11-02 | 2013-05-02 | Apple Inc. | Purchasing a product in a store using a mobile device |
US8669251B2 (en) | 2011-11-03 | 2014-03-11 | Genentech, Inc. | 8-fluorophthalazin-1(2H)-one compounds |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
AU2013207900B2 (en) | 2012-01-12 | 2017-12-07 | Cambridge Enterprise Limited | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase |
EP2895473A1 (en) | 2012-09-13 | 2015-07-22 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
BR112016012728A2 (pt) | 2013-12-05 | 2020-08-11 | Pharmacyclics Llc | compostos inibidores de tirosina quinase de bruton, composição farmacêutica os compreendendo e uso dos mesmos |
GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
WO2016196776A2 (en) | 2015-06-02 | 2016-12-08 | Pharmacyclics Llc. | Inhibitors of bruton's tyrosine kinase |
CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
MX2019004707A (es) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
WO2018098275A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
US11541051B2 (en) * | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
EP3743063A4 (en) | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND METHOD OF USING THEREOF |
US11479556B1 (en) | 2018-10-15 | 2022-10-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
US20220143195A1 (en) | 2019-02-13 | 2022-05-12 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
KR20210149757A (ko) | 2019-04-09 | 2021-12-09 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
CN114206855A (zh) | 2019-05-17 | 2022-03-18 | 紐力克斯治疗公司 | 用于Cbl-b抑制的氰基环丁基类化合物及其用途 |
AU2020303696A1 (en) | 2019-06-26 | 2022-01-06 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof |
US20220387395A1 (en) | 2019-07-30 | 2022-12-08 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
JP2022549007A (ja) | 2019-09-24 | 2022-11-22 | ニューリックス セラピューティクス,インコーポレイテッド | 養子細胞療法に使用するためのcbl阻害剤および組成物 |
US20230024442A1 (en) | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
AU2022310182A1 (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with diminished imid activity |
AU2022313210A1 (en) | 2021-07-23 | 2024-02-08 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
WO2023076303A1 (en) | 2021-10-26 | 2023-05-04 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
-
2019
- 2019-10-14 US US15/734,774 patent/US11479556B1/en active Active
- 2019-10-14 AU AU2019360928A patent/AU2019360928B2/en active Active
- 2019-10-14 BR BR112021007115-6A patent/BR112021007115A2/pt unknown
- 2019-10-14 EP EP19797494.2A patent/EP3867242A1/en active Pending
- 2019-10-14 CA CA3115526A patent/CA3115526A1/en active Pending
- 2019-10-14 JP JP2021545273A patent/JP2022508705A/ja active Pending
- 2019-10-14 BR BR122023024103-7A patent/BR122023024103A2/pt unknown
- 2019-10-14 MX MX2021004191A patent/MX2021004191A/es unknown
- 2019-10-14 KR KR1020217014388A patent/KR20210077719A/ko unknown
- 2019-10-14 WO PCT/US2019/056112 patent/WO2020081450A1/en unknown
- 2019-10-14 CN CN201980082722.7A patent/CN113412259A/zh active Pending
-
2021
- 2021-03-30 IL IL281904A patent/IL281904A/en unknown
-
2022
- 2022-07-28 US US17/876,433 patent/US11866442B2/en active Active
-
2023
- 2023-09-28 US US18/374,282 patent/US20240124475A1/en active Pending
- 2023-11-14 AU AU2023266254A patent/AU2023266254A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113412259A (zh) | 2021-09-17 |
AU2023266254A1 (en) | 2023-12-07 |
WO2020081450A1 (en) | 2020-04-23 |
US11479556B1 (en) | 2022-10-25 |
CA3115526A1 (en) | 2020-04-23 |
JP2022508705A (ja) | 2022-01-19 |
EP3867242A1 (en) | 2021-08-25 |
BR112021007115A2 (pt) | 2021-07-20 |
US20230029378A1 (en) | 2023-01-26 |
AU2019360928B2 (en) | 2023-11-09 |
KR20210077719A (ko) | 2021-06-25 |
AU2019360928A1 (en) | 2021-05-13 |
IL281904A (en) | 2021-05-31 |
US20240124475A1 (en) | 2024-04-18 |
BR122023024103A2 (pt) | 2024-02-20 |
US11866442B2 (en) | 2024-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021004191A (es) | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. | |
MX2022006672A (es) | Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina. | |
PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12017500724A1 (en) | Carbazole derivatives | |
MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
MX2022006768A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
PL1853232T3 (pl) | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. | |
MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
MX2022000712A (es) | Moduladores de nlrp3. | |
WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
MX2021008941A (es) | Moduladores gpr35. | |
WO2017106798A3 (en) | Compositions and methods for treating gluten intolerance and disorders arising therefrom | |
MX2020013684A (es) | Formulaciones/composiciones que comprenden ibrutinib. |